New Two-Drug combo aims to keep ovarian cancer at bay after chemotherapy

This study is testing whether taking two oral medications (fluzoparib and famitinib) as maintenance therapy can help delay the return of advanced ovarian cancer in women who responded well to their initial chemotherapy. The trial will enroll 43 women aged 18-75 who have advanced ovarian cancer that improved after first-line platinum chemotherapy. Participants will take both pills daily for up to two years to see if this combination helps keep the cancer from progressing longer than standard approaches.